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Breast cancer is the most frequently diagnosed can-
cer in women. Radiotherapy is an essential compo-
nent in the curative treatment algorithm. The current 
standard of care is radiotherapy, in the supine posi-
tion, to the whole breast by 3D conformal planning. 
However, several questions remain regarding dose 
delivery and technique optimization. Can patient 
positioning improve dose homogeneity? Can the 
prone position reduce error associated with patient 
breathing or decrease the dose to healthy organs and 
tissues? This study is designed to compare prone ver-
sus (conventional) supine treatment and the impact 
of respiratory motion in each position. The benefits 
of IMRT versus conventional 3D conformal plan-
ning (in each position) will be compared with re-
gards to dose delivery to the breast, dose to healthy 
organs and tissues and cost-efficiency regarding de-
partmental resources. The results of this study will 
serve for the standardization of breast radiotherapy 
techniques within the CHU-Liege.
For more information please contact:
Philippe Coucke
E-mail: pcoucke@chu.ulg.ac.be
a phase i trial of sunitinib, a tyrosine kinase inhibitor (tKi) combined with ionizing irradia-
tion in rectal cancer ; protocol Kirc 08-01
Rectal cancer – radiotherapy – phase I  – sunitinib – tyrosine kinase inhibitor
The standard treatment for locally advanced rectal 
cancer combines radiotherapy with surgery and che-
motherapy. It has been demonstrated that neoadju-
vant radiotherapy provides superior results compared 
to the post-operative setting. Sunitinib is a tyrosine 
kinase inhibitor with anti-angiogenic properties. In 
murine models, the combination of sunitnib and 
fractionated radiotherapy inhibits tumor regrowth. 
This phase I trial is therefore designed to combine 
conventional radiotherapy with concomitant suniti-
nib in a preoperative approach for locally advanced 
rectal cancer.
Eligibility criteria include a cT3 or N+ (confined 
to mesorectum) rectal adenocarcinoma considered 
amenable to a R0 low anterior resection. 
Three different doses of sunitinib (25, 37.5 and 
50mg) will be tested. The primary objective is to 
establish a recommended dose of sunitinib in these 
conditions. Secondary endpoints include overall sur-
vival, progression-free survival, downstaging and R0 
resection rate, gene expression and proteomics. These 
results will pave the way for the design of a phase II 
trial that can potentially combine radiotherapy, che-
motherapy and sunitinib in the neoadjuvant setting.
For more information please contact::
Philippe Coucke
E-mail: pcoucke@chu.ulg.ac.be 
overview of trials running in the Benelux
(BJMO 2009;Vol 3;3:117-123)
a dosimetric study comparing breast radiotherapy planned in the prone versus supine posi-
tions and via conformal 3D versus iMrt techniques; protocol B-Pos
Dosimetry – breast - radiotherapy – prone – supine – IMRT – gating
This multi-center phase III trial aims to assess 
the efficacy and tolerability of sorafenib in patients 
with resected renal cell carcinoma. Patients will be 
randomized to 3 treatment arms: 3 years placebo, 
sorcE trial: a Phase iii randomised double-blind study comparing sorafenib with placebo in 
patients with resected primary renal cell carcinoma at high or intermediate risk of relapse
Phase III – sorafenib – renal cell carcinoma – accrual ongoing
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1 year sorafenib + 2 years placebo or 3 years sora-
fenib. The main endpoints of the study are disease 
free survival,  RCC specific survival, overall survi-
val and toxicity.
For more information please contact:
Steven Joniau, study coordinator for Belgium
E-mail: steven.joniau@uz.kuleuven.ac.be
This multi-center phase III trial aims to  investi-
gate the potential benefit of a combined adjuvant 
treatment (short term androgen suppression and 
post-operative radiotherapy) for improving the bio-
chemical progression free survival of patients who 
have undergone radical prostatectomy for cT1-2-
3a N0M0 prostate cancer with baseline PSA ≤ 5 x 
upper limit of normal range and who present post-
operatively with pathologic stage pT2 R1 / pT3-b 
R0-1 N0M0, Gleason score 5-10 and an undetect-
able post-operative PSA.
Patients will be randomized between post-operative 
irriadiation alone or post-operative irradiation and 
short term adjuvant androgen deprivation.
The main endpoints of the  study  are  biochemical 
and clinical progression-free survival,  distant-me-
tastases-free survival, overall survival and toxicity.
For more information please contact:
Hendrik Van Poppel, Michel Bolla, study coordinators 
E-mail:hendrik.vanpoppel@uz.kuleuven.ac.be; 
MBolla@chu-grenoble.fr
Eortc 22043-30041 trial: Post-operative external radiotherapy combined with concomi-
tant and adjuvant hormonal treatment versus post-operative external radiotherapy alone in 
pathological stage pt3a-b r0-1 n0M0, Gleason score 5-10 prostatic carcinoma
Phase III – prostate cancer – radiotherapy - hormonotherapy - accrual start: May-June 2009
Exelixis trial 184-301: a promising experimental treatment option for patients with medul-
lary thyroid carcinoma (Mtc)
XL-184 – medullary thyroid carcinoma – tyrosine kinase inhibitor
XL-184 is a multi-targeted oral tyrosine kinase in-
hibitor against RET, MET, VEGFR2/KDR and 
KIT. The drug is available since 29-01-2009 (trial 
initiation date) in the framework of a double-blind, 
randomized, placebo-controlled phase III study for 
a global total of 315 patients. This is a registration 
trial. In a previous landmark phase I study per-
formed  by Exelixis, a biotech company from the 
United States, the vast majority of patients showed 
significant shrinkage of their MTC metastasis in-
cluding objective RECIST responses, achieved ex-
cellent symptom control and impressive biochemi-
cal responses. This work has been featured at various 
prestigious meetings, including ASCO 2008 in 
Chicago and the EORTC NCI AACR Symposium 
in Geneva last year.
The  drug “competes” with similar agents from 
other companies, which have recently been explored 
in Phase II/III trials, which do not recruit further 
patients anymore. Patients who failed treatment 
with other agents (or screening for similar trials), 
including various tyrosine kinase inhibitors or mo-
noclonal antibodies, are not  automatically excluded 
from participation in this trial.
The exelixis trial 184-301 recruits patients with MTC 
who fulfill the following major inclusion criteria:
•	Histologically	confirmed	MTC	that	is	unresecta-
ble, locally advanced or metastatic & measurable 
or non-measurable by modified RECIST 
•	 18	years	old	or	older	
•	 ECOG	0,	1	or	2
•	 Progressive	 disease	 on	 CT,	 MRI,	 bone	 scan	 or	 
X-ray per mRECIST at screening compared to an 
image done within previous 14 months
•	 Clinically	significant	adverse	events	due	to	anti-neo-
plastic agents, investigational drugs or other medica-
tions have recovered to CTCAE v3.0 Grade ≤ 1
•	ANC	(Absolute	Neutrophil	Count)	≥	1500/mm³
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•	 Platelets	≥	100,000/mm³
•	Hemoglobin	≥	9	g/dL	





dically accepted contraception during & for 3 months 
after treatment (excludes women not of childbearing 
potential and men who have been sterilized)
•	No	other	malignancy	&	currently	no	evidence	of	
malignancy (except non-melanoma skin cancer or 
carcinoma in situ of the cervix).
•	 Female	subjects	of	childbearing	potential	must	have	
a negative pregnancy test at screening. Females of 
childbearing potential are defined as sexually ma-
ture women without prior hysterectomy or who have 
had any evidence of menses in the past 12 months. 
Women who have been amenorrheic for 12 or more 
months are still considered to be of childbearing 
potential if the amenorrhea is possibly due to prior 
chemotherapy, anti-estrogens or ovarian suppression
Patients are excluded from trial participation in case of:
•	 Systemic	 anti-tumor	 therapy	 (chemotherapy,	 
biologic modifiers or anti-angiogenic therapy) 
within 4 weeks of randomization (6 weeks - 
Nitrosoureas or mitomycin C)
•	Radiation	to	≥	25%	of	bone	marrow
•	Treatment	 with	 other	 investigational	 agents	 




mization & stable without steroid or anti-convul-
sant	for	≥	10	days	
•	 Clinically	significant	hematemesis	or	recent	history	
of hemoptysis of >2.5 mL of red blood or other signs 
of pulmonary hemorrhage or endobronchial lesion(s)
•	Urine	protein/creatinine	ratio	of	≥	1
•	 Serious	intercurrent	illness	such	as:	Hypertension	
(> 2 readings at screening of > 140 mmHg systolic 
or > 90 mmHg diastolic) despite optimal treat-
ment; unhealed wounds from recent surgery; car-
diac arrhythmias
•	Recent	history	of	serious	disease	such	as:	sympto-
matic congestive heart failure or unstable angina 
pectoris within the past 3 months or;  MI, stroke 
or TIA within the past 6 months
•	 Pregnant	or	breastfeeding
•	Active	infection	requiring	systemic	treatment
•	Known	 allergy	 or	 hypersensitivity	 to	 any	 of	 the	
components of the XL184 or placebo formulations 
•	 Incapable	 of	 understanding	 and	 complying	 with	
the protocol or unable to provide informed consent 
The experimental compound is given daily at a dose 
of 175 mg p.o. (4 capsules). Due to the good safety 
profile of this drug treatment does not require any 
co-medication. 
The trial has a few methodological pitfalls:
•	Deviations	from	the	patient	selection	criteria	des-
cribed above will not be allowed (no waivers).
•	 FDA	requested	not	to	cross-over	patients	from	the	
placebo arm to the experimental  treatment arm 
(1:2 randomization) in case of disease progression, 
which means that 1/3 of patients will receive no 
active treatment.
•	The	 complex	 screening	procedures	must	be	 com-
pleted within 28 days, including shipment of biolo-
gical samples, central review of digital images etc.
•	At	least	10	unstained	slides	of	archival	tumor	tis-
sue are required within a very tight deadline .
•	All	study-specific	procedures	will	have	to	be	per-
formed on site in Leuven.
•	The	selection	of	 sites	participating	 in	 this	global	
registration study has been completed.
Patients with MTC, who basically comply with 
the patient selection criteria mentioned above, 
can be send to the consultation of prof Schöffski, 
accompanied by 10 unstained, archived tumor 
slides (or a paraffin block) and previous spiral CT 
scans on CD-ROM demonstrating disease pro-
gression. They will received detailed information 
about all aspects of the complex trial and – if in-
terested in participation – will undergo the infor-
med consent and screening procedures. You will 
receive continuous follow-up information of these 
patients.
For more information please contact::
Patrick Schöffski
E-mail: patrick.schoffski@uz.kuleuven.be
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cUP trial: molecular profiling as a strategy for the identification of primary solid tumor in 
metastatic cancer patients
Carcinoma of unknown primary - phase II -  molecular profiling - CupPrint®
Carcinoma of unknown primary (CUP) is defined 
by the presence of biopsy proven metastatic disease 
without an identifiable primary tumor site on its 
presentation. Molecular profiling of the tumor is a 
promising tool for helping clinicians to better decide 
the patients’ diagnosis and treatment. 
Gene expression analysis of the tumor is a promis-
ing new approach to identify the tumor origin. This 
technique (CupPrint®) can accurately predict the site 
of	primary	tumor	in	78	to	90%	of	cases.
The CUP trial, is a prospective phase II clinical trial 
that will evaluate the accuracy and costs of molecu-
lar profiling as a diagnostic method, compared to 
the traditional standard investigations in patients 
with metastatic tumors for whom the primary tu-
mor is identified by routine exams. The results of 
molecular profiling will not affect the treatment de-
cision. Investigators will have access to CupPrint® 
results only after they have identified and reported 
the primary tumor. If no primary tumor is found by 
all means of clinical investigation, physicians will be 
allowed to access CupPrint® result to help defining 
treatment.
For more information please contact::





2 trials with intra-arterial (ia) chemotherapy for unresectable isolated liver metastases from 
colorectal cancer.
Phase II – colorectal cancer – liver metastases – cetuximab - oxaliplatin
cHoicE study
The CHOICE study is a multicentric Phase II study 
(Promotor: IGR – Villejuif, France) including 45 
colorectal cancer patients with liver isolated metastases 
in which the primary tumor was removed (first line 
of treatment). No amendments regarding the K-ras 
status of the tumor. Patients will be treated as follows:
 IV: LV5FU2 + weekly cetuximab (provided by 
Merck)
 IA: oxaliplatin (q 2 weeks)
oPtiliV study
The OPTILIV study is muliticentric phase II study 
(Promotor: ARTBC international- Hop. P.Brousse, 
Villejuif, France) in which 60 colorectal cancer 
patients with liver isolated metastases are recrui-
ted in which the primary tumor was removed (Xth 
treatment line)
No amendments regarding the K-ras status of the 
tumor. Patients will be treated as follows:
 IV: bi-weekly cetuximab (provided 
 by Merck)
 IA: 5FU + irinotecan + oxaliplatin (q 2 
 weeks); chronomodulated schedule optional
For more information please contact:  
C. Focan & G. Demolin, study coordinators
E-mail: christian.focan@chc.be
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a phase i trial on lBH 589 (panobinostat), a histone deacetylase inhibitor (HDaci) in com-
bination with external radiotherapy for the treatment of prostate cancer, esophageal cancer 
and head and neck cancer. Protocol clBH589cBE01.
Histones - deacytase inhibitor - radiotherapy - phase I trial
Radiotherapy is a keystone in the treatment of prostate 
cancer (PC), esophageal cancer (EC) and head and 
neck cancer (H&N). In PC, LBH589 degrades andro-
gen receptors, a key regulator for cancer cell survival 
and proliferation. In squamous cell cancer, LBH589 is 
synergistic with radiation in preclinical models. Gen-
erally there is a strong rationale to use pan-HDACi 
(Histone deacytelase inhibitor) in H&N and gastroin-
testinal cancer. A phase I trial designed to assess the 
feasibility of combined administration of different oral 
LBH589 dosages in combination with ionizing irra-
diation in a selection of patients with PC, H&N and 
EC is currently starting at CHU-Liège. This will allow 
the optimal dose-establishment for further studies.
For more information please contact::  
Philippe A. Coucke, study coordinator
E-mail: pcoucke@chu.ulg.ac.be
assessing the efficacy of the combination of gemcitabine and cetuximab (EcHo) in advan-
ced cholangiocarcinoma
Gemcitabine – cetuximab – cholangiocarcinoma – BGDO – phase II
The Belgian Group of Digestive Oncology (BGDO) 
is launching a phase II trial assessing the efficacy 
of the combination of gemcitabine and cetuximab 
in advanced cholangiocarcinoma: the ECHO trial. 
These rare tumors represent an orphan disease, 
with no “standard” treatment and only phase II 
trials in the literature. If efficacy is shown after the 
first 13 patients, this study will hopefully include 
45 patients. The aim of the study will be to assess 




of the cases, translational research will also be per-
formed to see if mutated Ki-Ras can be predictive 
of response.
For more information please contact::  




FiElt study: First line inhibitor of EGFr in lung cancer treatment 
NSCLC – EGFR mutation - EGFR-1 tyrosine kinase inhibition –phase II
The FIELT study is a multicentre prospective phase 
II study evaluating small molecule EGFR-1 tyrosine 
kinase inhibition as first-line treatment in patients 
with advanced non-small cell lung cancer (NSCLC) 
harbouring a mutant EGFR gene. Patients with ad-
enocarcinoma of the lung with little (< 15 packyears) 
or no smoking history are genotyped for mutations in 
EGFR in the central VUB lab. This is performed on 
the normal formalin fixed lung cancer biopsies used 
for diagnosis. The results are returned within maxi-
mally 2 weeks. FISH analysis will also be performed 
The patients with an EGFR mutation are then eligible 
for first-line treatment with erlotinib.The primary end-
point of this trial is progression free survival.
 
For more information please contact::  
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Therapeutic options in patients with advanced eso- 
phageal cancer, melanoma and sarcoma are limited 
after failure of standard first line chemotherapy. In 
the present, multicentric two-stage phase II trial 
the activity of single agent sunitinib malate (Sutent®) 
administered orally at 50 mg/day, 4 weeks on fol-
lowed by 2 weeks off will be examined.
Inclusion Criteria:
•	Advanced cancer, locally or metastatic
•	Presence of plasma and tissue sample
•	Life expectancy of > 3 months
•	Measurable disease or disease evaluable with non-
measurable lesions or tumor marker
•	Disease progression on prior treatment and anti-
cancer therapy-free period of > 4 weeks before 
baseline examination for current study.
•	Tumor- specific inclusion criteria: 
- Sarcoma: Second line, after one line of anthra-
cycline based chemotherapy
- Melanoma: Second line, after one line chemo-
therapy containing DTIC (combination or sin-
gle agent). Prior vaccination and anti-CTLA4 
immune therapy allowed (requires establish-
ment of progressive disease under treatment).
- Esophageal cancer: Second line after cispla-
tinum based chemotherapy
The study comprises a translational component 
including 
•	Baseline plasma levels of VEGF-A, sVEGFR-2, 
sVEGFR-3 and PlGF (placenta growth factor)
•	Tumor gene copy number of VEGFR-2
•	Evolution during treatment of circulating en-
dothelial and tumor cells. Perfusion imaging with 
dynamic contrast enhanced MRI.
For more information please contact:
Ellen Dewandeler, datamanager
E-mail: Ellen.DeWandeler@uzbrussel.be
activity of sunitinib in esophageal cancer, melanoma and sarcoma (sEMs) 
Phase II – sunitinib - esophageal cancer – melanoma - sarcoma
the PatsGo trial
Temozolomide – Phase II – chemotherapy – glioblastoma – progression-free survival
The PATSGO trial is a randomized phase II trial 
evaluating the benefit of a prolonged adjuvant treat-
ment in glioblastoma patients. Some patients present 
at the end of the 6 months adjuvant treatment with 
residual tumors that are still regressing. These pa-
tients could benefit from prolonged treatment. This 
study will also evaluate the efficacy of rechallenging 
patients with temozolomide when their tumor pro-
gresses. As temozolomide is thought to be inactive 
at relapse, most relapsing patients do not receive it. 
However, some responses have been reported. The 
major enpoints of this trial are (1) progression-free 
and overall survival at 6 months; (2) safety and ad-
verse event profile of prolonged adjuvant temozolo-
mide; (3) comparison of the Health-Related Quality 
of Life of the patients randomized in the 2 arms; 
(4) overall tumor response in patients when they are 
rechallenged with temozolomide.
For more information please contact:
J-Fr. Baurain, study coordinator
E-mail: jean-francois.baurain@uclouvain.be
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the solE trial
Letrozole – phase III trial – endocrine therapy – early stage breast cancer – disease free survival
The SOLE trial is a phase III trial evaluating 
the role of continuous letrozole versus intermittent 
letrozole following 4 to 6 years of prior adjuvant 
endocrine therapy in postmenopausal women with 
hormone-receptor positive, node-positive, early stage 
breast cancer (SOLE / IBCSG 35-07 / BIG 1-07).
For more information please contact:
Guy Jerusalem, study coordinator for Belgium
E-mail: g.jerusalem@chu.ulg.ac.be
the VlK trial
Prospective trial - dose de-escalation – HNC – phase III – IG-IMRT – swallowing dysfunction
The VLK trial is an academic, multicentre, 
randomized, prospective phase III trial using 
image-guided, intensity-modulated radiotherapy 
(IG-IMRT) with dose de-escalation to the elective 
nodal sites, the swallowing apparatus and neck soft 
tissues for head and neck cancer. The hypothesis is 
that dose de-escalation on the elective nodal sites 
will decrease the rate and severity of swallowing 
disturbances while loco-regional control will re-
main equal.
For more information please contact:
Sandra Nuyts, study coordinator
E-mail  sandra.nuyts@uzleuven.be
GortEc 2006-01: a phase ii study of sU11248 in patients with recurrent and/or metastatic 
squamous head and neck carcinoma
phase II – open label – multicentre – head and neck cancer – recurrent or metastatic disease – 
toxicity and efficacy of sunitinib
Recurrent or metastatic head and neck cancer pa-
tients will receive sunitinib, an anti-VEGFR after 
they fail platinum-salt chemotherapy. Patients 
should have measurable lesions accessible to bi-
opsy. This is the first time that such treatment is 
given to these patients. Therefore, this European 
multicentre phase II study examines toxicity and 
efficacy.
For more information please contact:
J-P. Machiels, study coordinator
E-mail: jean-pascal.machiels@uclouvain.be
The department of general medical oncology of the University Hospitals Leu-
ven has generated a list of recently closed, currently ongoing and prospective clinical 
trials of our department. This overview can be consulted through the following link: 
http://www.uzleuven.be/nl/ig-algemeen-medische-oncologie/klinische-studies
The list provides an overview of the clinical trials in non-disease specific, disease-specific and com-
passionate use programs.
It is a useful tool for general practitioners as well as patients themselves looking for more information 
on the internet.
